CN105232677A - Traditional Chinese medicine composition for treating myocardial infarction and preparation method of traditional Chinese medicine composition - Google Patents
Traditional Chinese medicine composition for treating myocardial infarction and preparation method of traditional Chinese medicine composition Download PDFInfo
- Publication number
- CN105232677A CN105232677A CN201510651817.XA CN201510651817A CN105232677A CN 105232677 A CN105232677 A CN 105232677A CN 201510651817 A CN201510651817 A CN 201510651817A CN 105232677 A CN105232677 A CN 105232677A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- fructus
- medicine composition
- caulis spatholobi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/10—Bryophyta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/486—Millettia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/714—Aconitum (monkshood)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Abstract
The invention relates to a traditional Chinese medicine composition for treating myocardial infarction and a preparation method of the traditional Chinese medicine composition, and belongs to the technical field of traditional Chinese medicine. The traditional Chinese medicine composition is prepared from caulis spatholobi, burdock, panax notoginseng, fennel, coptis chinensis, hawthorn, cornus officinalis, cinnamomum cassia, monkshood, rhodobryum roseum and licorice root. The traditional Chinese medicine composition has efficacy of activating blood and removing stasis and invigorating spleen and replenishing qi, and has the advantages of being good in curative effect, low in side effect, convenient to take, easy to popularize and apply and the like.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition for the treatment of myocardial infarction and preparation method thereof, belong to technical field of Chinese medicines.
Background technology
Myocardial infarction is the disease of the part myocardial necrosis caused due to the lasting severe ischemic of cardiac muscle, multiple be born in the middle age after, have the symptom such as the similar anginal front chest pain of violent and lasting character, cardiopalmus, asthma, weak and faint pulse, blood pressure reduction during morbidity.Primary disease incidence rate has and increases trend year by year, and arteriosclerosis accounts for 98% of Pathogenesis of Acute Myocardial Infarction rate, and patient more than 40 years old is in the majority, and many with hypertension, and nearly half is angor medical history intentionally.
In treatment, be broadly divided into two classes: one is take stopgap measures and effect a permanent cure, i.e. " symptomatic treatment in acute condition, radical treatment in chronic case "; Two is routine treatment and contrary treatment, i.e. " treating with drugs opposite to the nature of disease is called routine treatment, contrary treatment means that the remedy coincides with the pseudo-symptom of disease ", and the one that routine treatment is its disease character inverse and controls commonly uses therapeutic rules, and contrary treatment is a kind of Therapeutic Method of being obedient to disease illusion and controlling.The present traditional Chinese medical science thinks that the main pathogenesis of coronary heart disease myocardial infarction is deficiency in origin and excess in superficiality, and deficiency in origin is based on the deficiency of vital energy, the deficiency of YIN, and mark is real turbid common with the stagnation of QI, blood stasis, expectorant.The ancient prescription traditional Chinese medical science proposes phlegm and blood stasis theory, thinks body fluid transporting mistake department, stops poly-ly forming expectorant; Escape of blood from meridians, stays in arteries and veins outer or stagnant in arteries and veins, causes blood stasis expectorant to stop or expectorant is poly-hinders blood; Or the expectorant stasis of blood is changed mutually, stagnant in passages through which vital energy circulates to expectorant stasis blocking eventually, phlegm and blood stasis and causing a disease; And myocardial infarction be divided into type of deficiency of both QI and YIN, deficiency of YANG QI weak type, the expectorant stasis of blood to hand over three types such as resistance qi stagnation and blood stasis type, control respectively with supplementing QI and nourishing YIN, QI invigorating warming YANG, dissipating phlegm and removing blood stasis.
China applies for a patent 201410113088.8 and discloses a kind of Chinese medicine composition for the treatment of myocardial infarction, its raw materials comprises: Galla Chinensis, Flos Lonicerae, the Cortex Eucommiae, Radix Cirsii Japonici, Rhizoma Chuanxiong, Radix Rehmanniae, Periostracum Cicadae, Poria, the Radix Paeoniae Alba, Radix Codonopsis and Radix Glycyrrhizae, this Chinese medicine composition has good therapeutic effect in treatment myocardial infarction, there is significant clinical generalization value, but the effect in supplementing QI and nourishing YIN, blood circulation promoting and blood stasis dispelling etc. not very remarkable.
Summary of the invention
The technical problem to be solved in the present invention is to provide a kind of Chinese medicine composition for the treatment of myocardial infarction, this Chinese medicine composition has effect of blood circulation promoting and blood stasis dispelling and invigorating the spleen and replenishing QI, also have that good effect, side effect are low, taking convenience and be easy to advantages such as applying, in addition, the present invention also provides corresponding manufacturing process to be made and facilitate easy-to-use preparation under the prerequisite ensureing curative effect by this pharmaceutical composition.
Chinese medicine composition of the present invention is prepared from by the raw material of following parts by weight: Caulis Spatholobi 10-15 part, Fructus Arctii 6-15 part, Radix Notoginseng 10-15 part, Fructus Foeniculi 6-15 part, Rhizoma Coptidis 3-9 part, Fructus Crataegi 9-12 part, Fructus Corni 6-12 part, Cortex Cinnamomi 6-12 part, Radix Aconiti Lateralis Preparata 3-10 part, Rhodobryum roseum Limpr. 6-9 part and Radix Glycyrrhizae 1-10 part.
Preferably, described Chinese medicine composition is prepared from by the raw material of following parts by weight: Caulis Spatholobi 10-12 part, Fructus Arctii 6-10 part, Radix Notoginseng 12-15 part, Fructus Foeniculi 6-10 part, Rhizoma Coptidis 3-6 part, Fructus Crataegi 9-10 part, Fructus Corni 10-12 part, Cortex Cinnamomi 8-12 part, Radix Aconiti Lateralis Preparata 5-10 part, Rhodobryum roseum Limpr. 6-8 part and Radix Glycyrrhizae 5-10 part.
Preferably, described Chinese medicine composition is prepared from by the raw material of following parts by weight: Caulis Spatholobi 11 parts, Fructus Arctii 8 parts, Radix Notoginseng 13 parts, 9 parts, Fructus Foeniculi, Rhizoma Coptidis 5 parts, Fructus Crataegi 9 parts, Fructus Corni 11 parts, Cortex Cinnamomi 10 parts, Radix Aconiti Lateralis Preparata 7 parts, Rhodobryum roseum Limpr. 7 parts and 6 parts, Radix Glycyrrhizae.
Preferably, described Chinese medicine composition is prepared from by the raw material of following parts by weight: Caulis Spatholobi 12 parts, Fructus Arctii 10 parts, Radix Notoginseng 15 parts, 10 parts, Fructus Foeniculi, Rhizoma Coptidis 6 parts, Fructus Crataegi 10 parts, Fructus Corni 12 parts, Cortex Cinnamomi 12 parts, Radix Aconiti Lateralis Preparata 10 parts, Rhodobryum roseum Limpr. 8 parts and 10 parts, Radix Glycyrrhizae.
Preferably, described Chinese medicine composition is made into tablet, capsule, drop pill, granule or powder.
Accordingly, the preparation method of Chinese medicine composition provided by the invention comprises the steps:
A) Caulis Spatholobi is taken, pulverize, adding medical material weight 2-5 times amount volume fraction is the alcoholic solution of 60-90%, add the cellulase of medical material weight 0.8%-1.5% again, lixiviate 1-3 hour at 38-45 DEG C, then at 85-95 DEG C of reflux, extract, 1-2 hour, filter and retain Caulis Spatholobi filtering residue, obtaining Caulis Spatholobi extracting solution;
B) Fructus Arctii, Radix Notoginseng, Fructus Foeniculi, Rhizoma Coptidis, Fructus Crataegi, Fructus Corni, Cortex Cinnamomi, Radix Aconiti Lateralis Preparata, Rhodobryum roseum Limpr. and Radix Glycyrrhizae is taken, add described Caulis Spatholobi filtering residue, pulverize, add 3-8 times amount heavy water and boil 1-5 hour, filter, obtain filtrate, the volume fraction adding 2-5 times of weight in filtering residue is the alcoholic solution of 60-90%, boils 30-60 minute, filters, obtain filtrate, merge twice filtrate;
C) described Caulis Spatholobi extracting solution and described twice filtrate are mixed, be concentrated into the thick paste that relative density is 1.20-1.35, drying under reduced pressure, cross 100-200 mesh sieve after pulverizing, obtain Chinese medicine composition of the present invention.
Source, the nature and flavor of the present invention's component used, return through and effect:
Caulis Spatholobi: this product is the dry rattan of leguminous plant spatholobus suberectus; Bitter in the mouth, sweet, warm in nature; Return liver, kidney channel; Enrich blood, invigorate blood circulation, dredging collateral.
Fructus Arctii: be Compositae draft taproot class plant, the fiber of Fructus Arctii can promote intestinal peristalsis, helps defecation, reduces body inner cholesterol, and minimizing toxin, refuse accumulate in vivo, reaches prevention of stroke and the effect of preventing and treating gastric cancer, uterus carcinoma.Doctor trained in Western medicine thinks that it is except having diuresis, removing food stagnancy, eliminating the phlegm except the pharmacological actions such as stopping leak, also for the dietetic therapy of constipation, hypertension, high-cholesterol disease.The traditional Chinese medical science thinks effects such as having wind-dispelling heat-dissipating, lung qi dispersing rash, resolving toxin and disinhibiting the throat.
Radix Notoginseng: be the dry root welding technology of panax araliaceae plant, has dissipating blood stasis hemostasis, effect of subduing swelling and relieving pain.In addition, also have comprise hemostasis, antithrombotic, promotion hemopoietic, expand blood vessel, blood pressure lowering, resist myocardial ischemia, anti-cerebral ischemia, arrhythmia, atherosclerosis, antiinflammatory, protect the liver, antitumor, the effect such as analgesia, principle active component is PNS, PDS, PTS and Radix Notoginseng propylhomoserin.
Fructus Foeniculi: main component is Oleum Anisi Stellati, energy stimulating gastrointestinal neural blood vessel, facilitating digestion liquid is secreted, and increases gastrointestinal peristalsis, gets rid of the gas accumulated, so there is effect of stomach invigorating, circulation of qi promoting; Sometimes gastrointestinal peristalsis can reduce again after excitement, thus contributes to alleviating spasm, easing the pain.Chinese medicine is used as medicine, and warm in nature, acrid in the mouth, returns liver,kidney,spleen, stomach warp; Function warming the liver kidney, warming the stomach gas, loose plug knot, dispersing cold for relieving pain, regulating qi-flowing for harmonizing stomach.Fructus Foeniculi also has antiulcer, analgesia, gonadotropic Effect etc., and Oleum Anisi Stellati has antibacterial action in various degree.Energy stimulating gastrointestinal neural blood vessel, promotes saliva and gastric secretion, plays appetite stimulator, digestive effect.Be applicable to Deficiency and coldness of spleen and stomach.
Rhizoma Coptidis: this product is the dry rhizome of ranunculaceae plant Rhizoma Coptidis; Bitter in the mouth, cold in nature; GUIXIN, spleen, stomach, liver, gallbladder, large intestine channel; Heat clearing and damp drying, eliminating fire and detoxication.
Fructus Crataegi: containing multiple organic acid.Oral rear enhancing gastric acidity, improves pepsin activity, promotes the digestion of protein; Fructus Crataegi sour in the mouth, stimulates gastric mucosa to promote gastric secretion; Fatty enzyme in Fructus Crataegi, can promote the digestion of fat; Fructus Crataegi contains the compositions such as vitamin C, oral can appetite stimulator; Fructus Crataegi has regulating action to gastrointestinal motility function, there is inhibitory action to the gastrointestinal smooth muscle of spasticity, have excitation to the smooth muscle of relaxed state, in addition, Fructus Crataegi flavone, hydrolyzate increase ischemic myocardium nutrient flow amount, wherein the strongest with the effect of Fructus Crataegi hydrolyzate.Fructus Crataegi, while increase coronary artery blood flow, can also reduce myocardial oxygen consumption, improves coefficient of oxygen utilization.
Fructus Corni: Fructus Corni officinalis contains abundant nutrient substance and functional component, the experience of the Compendium of Material Medica collection ancient Chinese medicine doctor application Fructus Corni of Ming Dynasty's Li Shizhen (1518-1593 A.D.), the medicine that Fructus Corni is classified as controlling nocturnal emission with astringent drugs of enriching blood, liver and kidney tonifying, regulating QI, tonify deficiency, improving eyesight and keeps fit.
Cortex Cinnamomi: be the dry bark of canella Cortex Cinnamomi; Acrid in the mouth, sweet, extremely hot in nature; Return kidney, spleen, the heart, Liver Channel; Mend fire supporing yang, let the fire back to its origin, dispersing cold for relieving pain, promoting blood circulation to restore menstrual flow.
Radix Aconiti Lateralis Preparata: have another name called Aconitum carmichjaelii Debx. or Radix Aconiti Lateralis Preparata, the processed goods of the daughter root of Ranunculaceae, aconitum plant.Function cures mainly: recuperating depleted YANG and rescuing the patient from collapse, mend fire supporing yang, dispersing cold for relieving pain.
Rhodobryum roseum Limpr.: be a kind of Chinese herbal medicine, plant body is little, the micro-hardship of taste, can as the treatment of heart disease or other mental disorder.Specially control that heart disease is nervous, cardiopalmus, the symptoms such as neurasthenia.
Radix Glycyrrhizae: be the dry root of glycyrrhizic legume, Glycyrrhiza inflata Bat. or Glycyrrhiza glabra L., Radix Glycyrrhizae contains glycyrrhizic acid, liquiritin isoreactivity composition, has the effects such as heat-clearing and toxic substances removing, invigorating the spleen and replenishing QI, expelling phlegm for arresting cough.
Compared with prior art, the present invention has following beneficial effect:
1, compared with the Chinese medicine of existing other treatment myocardial infarction, Chinese medicine composition of the present invention has remarkable efficacy in blood circulation promoting and blood stasis dispelling and invigorating the spleen and replenishing QI etc.
2, compared with chemotherapeutic agent, Chinese medicine composition of the present invention is natural pure Chinese medicinal preparation, untoward reaction significantly reduces, and Chinese medicine composition effect of the present invention is comprehensive, medication effect is better, treat myocardial infarction disease from root, there is good effect, taking convenience and be easy to advantages such as applying.
Detailed description of the invention
It will be understood by those skilled in the art that technology disclosed in following examples represents the technology playing good action in the practice of the invention of the present inventor's discovery.But, many changes can be made in disclosed specific embodiments, and still obtain same or analogous result, and not depart from the spirit and scope of the present invention.
embodiment 1
Chinese medicine composition of the present invention is prepared from by the raw material of following parts by weight: Caulis Spatholobi 10 parts, Fructus Arctii 10 parts, Radix Notoginseng 15 parts, 6 parts, Fructus Foeniculi, Rhizoma Coptidis 6 parts, Fructus Crataegi 9 parts, Fructus Corni 10 parts, Cortex Cinnamomi 12 parts, Radix Aconiti Lateralis Preparata 5 parts, Rhodobryum roseum Limpr. 6 parts and 5 parts, Radix Glycyrrhizae.
Preparation method comprises the steps:
A) take Caulis Spatholobi, pulverize, adding medical material weight 5 times amount volume fraction is the ethanol of 75%, add the cellulase of medical material weight 1% again, lixiviate 2 hours at 42 DEG C, then 90 DEG C of reflux, extract, 2 hours, filter and retain Caulis Spatholobi filtering residue, obtaining Caulis Spatholobi extracting solution;
B) Fructus Arctii, Radix Notoginseng, Fructus Foeniculi, Rhizoma Coptidis, Fructus Crataegi, Fructus Corni, Cortex Cinnamomi, Radix Aconiti Lateralis Preparata, Rhodobryum roseum Limpr. and Radix Glycyrrhizae is taken, add described Caulis Spatholobi filtering residue, pulverize, add 6 times of weight water and boil 3 hours, filter, obtain filtrate, the volume fraction adding 2 times of weight in filtering residue is the ethanol of 75%, boils 45 minutes, filters, obtain filtrate, merge twice filtrate;
C) described Caulis Spatholobi extracting solution and described twice filtrate are mixed, be concentrated into the thick paste that relative density is 1.25, drying under reduced pressure, cross 100 mesh sieves after pulverizing, obtain Chinese medicine composition of the present invention.
embodiment 2
Chinese medicine composition of the present invention is prepared from by the raw material of following parts by weight: Caulis Spatholobi 11 parts, Fructus Arctii 8 parts, Radix Notoginseng 13 parts, 9 parts, Fructus Foeniculi, Rhizoma Coptidis 5 parts, Fructus Crataegi 9 parts, Fructus Corni 11 parts, Cortex Cinnamomi 10 parts, Radix Aconiti Lateralis Preparata 7 parts, Rhodobryum roseum Limpr. 7 parts and 6 parts, Radix Glycyrrhizae.
Preparation method is similar to Example 1.
embodiment 3
Chinese medicine composition of the present invention is prepared from by the raw material of following parts by weight: Caulis Spatholobi 12 parts, Fructus Arctii 10 parts, Radix Notoginseng 15 parts, 10 parts, Fructus Foeniculi, Rhizoma Coptidis 6 parts, Fructus Crataegi 10 parts, Fructus Corni 12 parts, Cortex Cinnamomi 12 parts, Radix Aconiti Lateralis Preparata 10 parts, Rhodobryum roseum Limpr. 8 parts and 10 parts, Radix Glycyrrhizae.
Preparation method is similar to Example 1.
clinical observation on the therapeutic effect
1, case selection: in 300 routine myocardial infarction clinical patients volunteers, male 150 example, female patient 150 example, age bracket be 40-60 year, all patients all has typical myocardial infarction clinical symptoms, and in sex, age, the course of disease no difference of science of statistics.
2, diagnostic criteria:
(1) typical myocardial ischemia symptom (chest pain or discomfort uncomfortable in chest);
(2) typical cardiac electrical figure change;
(3) Serum fibrosis markers raises.
3, efficacy assessment standard:
Cure: after drug administration, malaise symptoms disappears completely;
Effective: after drug administration, malaise symptoms alleviates or partial disappearance;
Invalid: after drug administration, malaise symptoms is unchanged;
Total effective rate=(cure+effectively)/total number of cases × 100%.
4, instructions of taking: 300 patient volunteers are divided into 3 groups at random, often organize 100 people, is respectively treatment A group, treatment B group and positive controls, treatment A group, treatment B component do not take the Chinese medicine composition that the embodiment of the present invention 2,3 prepares, every day 3 times, each 10-20g, serve on 1 month.Positive controls takes FUFANG DANSHEN DIWAN (Tianjin Tasly Pharmaceutical Co., Ltd, the accurate word Z10950111 of traditional Chinese medicines), and oral or sublingual administration, 10 balls, 3 times on the one, serve on 1 month.
5, therapeutic outcome: as shown in table 1.
Table 1 therapeutic outcome
Compared by the therapeutic effect of Chinese medicine composition of the present invention and FUFANG DANSHEN DIWAN, the significant curative effect of traditional Chinese medicine composition for treating myocardial infarction aspect of the present invention can be found out.The cure rate of Chinese medicine composition of the present invention reaches more than 80%, total effective rate reaches more than 90%, higher than cure rate and the total effective rate of positive controls, wherein best with the therapeutic effect for the treatment of A group, visible, the good effect of Chinese medicine composition of the present invention, cure rate is high, can be used as the medicine for the treatment of myocardial infarction.
Owing to describing the present invention by above preferred embodiment, in spirit of the present invention and/or scope, any for replacement/of the present invention or combination implement the present invention, be all apparent for a person skilled in the art, and be included among the present invention.
Claims (6)
1. treat the Chinese medicine composition of myocardial infarction for one kind, it is characterized in that, be prepared from by the raw material of following parts by weight: Caulis Spatholobi 10-15 part, Fructus Arctii 6-15 part, Radix Notoginseng 10-15 part, Fructus Foeniculi 6-15 part, Rhizoma Coptidis 3-9 part, Fructus Crataegi 9-12 part, Fructus Corni 6-12 part, Cortex Cinnamomi 6-12 part, Radix Aconiti Lateralis Preparata 3-10 part, Rhodobryum roseum Limpr. 6-9 part and Radix Glycyrrhizae 1-10 part.
2. the Chinese medicine composition for the treatment of myocardial infarction as claimed in claim 1, it is characterized in that, be prepared from by the raw material of following parts by weight: Caulis Spatholobi 10-12 part, Fructus Arctii 6-10 part, Radix Notoginseng 12-15 part, Fructus Foeniculi 6-10 part, Rhizoma Coptidis 3-6 part, Fructus Crataegi 9-10 part, Fructus Corni 10-12 part, Cortex Cinnamomi 8-12 part, Radix Aconiti Lateralis Preparata 5-10 part, Rhodobryum roseum Limpr. 6-8 part and Radix Glycyrrhizae 5-10 part.
3. the Chinese medicine composition for the treatment of myocardial infarction as claimed in claim 2, it is characterized in that, be prepared from by the raw material of following parts by weight: Caulis Spatholobi 11 parts, Fructus Arctii 8 parts, Radix Notoginseng 13 parts, 9 parts, Fructus Foeniculi, Rhizoma Coptidis 5 parts, Fructus Crataegi 9 parts, Fructus Corni 11 parts, Cortex Cinnamomi 10 parts, Radix Aconiti Lateralis Preparata 7 parts, Rhodobryum roseum Limpr. 7 parts and 6 parts, Radix Glycyrrhizae.
4. the Chinese medicine composition for the treatment of myocardial infarction as claimed in claim 2, it is characterized in that, be prepared from by the raw material of following parts by weight: Caulis Spatholobi 12 parts, Fructus Arctii 10 parts, Radix Notoginseng 15 parts, 10 parts, Fructus Foeniculi, Rhizoma Coptidis 6 parts, Fructus Crataegi 10 parts, Fructus Corni 12 parts, Cortex Cinnamomi 12 parts, Radix Aconiti Lateralis Preparata 10 parts, Rhodobryum roseum Limpr. 8 parts and 10 parts, Radix Glycyrrhizae.
5. the Chinese medicine composition of the treatment myocardial infarction as described in any one of claim 1-4, is characterized in that: described Chinese medicine composition is made into tablet, capsule, drop pill, granule or powder.
6. prepare a method for the Chinese medicine composition of the treatment myocardial infarction as described in any one of claim 1-4, it is characterized in that comprising the steps:
A) Caulis Spatholobi is taken, pulverize, adding medical material weight 2-5 times amount volume fraction is the alcoholic solution of 60-90%, add the cellulase of medical material weight 0.8%-1.5% again, lixiviate 1-3 hour at 38-45 DEG C, then at 85-95 DEG C of reflux, extract, 1-2 hour, filter and retain Caulis Spatholobi filtering residue, obtaining Caulis Spatholobi extracting solution;
B) Fructus Arctii, Radix Notoginseng, Fructus Foeniculi, Rhizoma Coptidis, Fructus Crataegi, Fructus Corni, Cortex Cinnamomi, Radix Aconiti Lateralis Preparata, Rhodobryum roseum Limpr. and Radix Glycyrrhizae is taken, add described Caulis Spatholobi filtering residue, pulverize, add 3-8 times amount heavy water and boil 1-5 hour, filter, obtain filtrate, the volume fraction adding 2-5 times of weight in filtering residue is the alcoholic solution of 60-90%, boils 30-60 minute, filters, obtain filtrate, merge twice filtrate;
C) described Caulis Spatholobi extracting solution and described twice filtrate are mixed, be concentrated into the thick paste that relative density is 1.20-1.35, drying under reduced pressure, cross 100-200 mesh sieve after pulverizing, obtain Chinese medicine composition of the present invention.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510651817.XA CN105232677A (en) | 2015-10-10 | 2015-10-10 | Traditional Chinese medicine composition for treating myocardial infarction and preparation method of traditional Chinese medicine composition |
| CN201610306368.XA CN105796685A (en) | 2015-10-10 | 2015-10-10 | Method for preparing traditional Chinese medicine composition for treating myocardial infarction |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510651817.XA CN105232677A (en) | 2015-10-10 | 2015-10-10 | Traditional Chinese medicine composition for treating myocardial infarction and preparation method of traditional Chinese medicine composition |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610306368.XA Division CN105796685A (en) | 2015-10-10 | 2015-10-10 | Method for preparing traditional Chinese medicine composition for treating myocardial infarction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105232677A true CN105232677A (en) | 2016-01-13 |
Family
ID=55030675
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510651817.XA Withdrawn CN105232677A (en) | 2015-10-10 | 2015-10-10 | Traditional Chinese medicine composition for treating myocardial infarction and preparation method of traditional Chinese medicine composition |
| CN201610306368.XA Withdrawn CN105796685A (en) | 2015-10-10 | 2015-10-10 | Method for preparing traditional Chinese medicine composition for treating myocardial infarction |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610306368.XA Withdrawn CN105796685A (en) | 2015-10-10 | 2015-10-10 | Method for preparing traditional Chinese medicine composition for treating myocardial infarction |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN105232677A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105213769A (en) * | 2015-09-29 | 2016-01-06 | 罗奕珺 | A kind of Chinese medicine composition for the treatment of myocardial infarction and preparation method thereof |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111467422A (en) * | 2020-04-29 | 2020-07-31 | 佛山科学技术学院 | Traditional Chinese medicine composition for treating myocardial infarction, pharmaceutical preparation and preparation method thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102961540A (en) * | 2012-11-29 | 2013-03-13 | 广西东兴市创新特色医药科技发展有限公司 | Medicine for treating coronary heart disease and preparation method for same |
| CN103816280A (en) * | 2014-03-25 | 2014-05-28 | 崔新明 | Traditional Chinese medicine composition for treating myocardial infarction and application of traditional Chinese medicine composition |
| CN104225507A (en) * | 2014-10-13 | 2014-12-24 | 崔银方 | Chinese medicine for treating limb paralysis and pain caused by cerebral hemorrhage |
| CN104225212A (en) * | 2014-09-25 | 2014-12-24 | 刘会焕 | Traditional Chinese medicine composition for treating miocardial infarction |
| CN104887747A (en) * | 2015-07-06 | 2015-09-09 | 苗怡文 | Traditional Chinese medicine composition for treating cerebral thrombosis and preparation method therefor |
| CN104940597A (en) * | 2015-07-27 | 2015-09-30 | 青岛蓝盛洋医药生物科技有限责任公司 | Chinese herbal composition used for treating myocardial infarction, and preparation method of Chinese herbal composition |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101716236B (en) * | 2009-12-18 | 2012-06-27 | 潘根起 | Chinese medicinal composition for adjunctively treating left ventricular insufficiency after acute myocardial infarction and preparation method thereof |
-
2015
- 2015-10-10 CN CN201510651817.XA patent/CN105232677A/en not_active Withdrawn
- 2015-10-10 CN CN201610306368.XA patent/CN105796685A/en not_active Withdrawn
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102961540A (en) * | 2012-11-29 | 2013-03-13 | 广西东兴市创新特色医药科技发展有限公司 | Medicine for treating coronary heart disease and preparation method for same |
| CN103816280A (en) * | 2014-03-25 | 2014-05-28 | 崔新明 | Traditional Chinese medicine composition for treating myocardial infarction and application of traditional Chinese medicine composition |
| CN104225212A (en) * | 2014-09-25 | 2014-12-24 | 刘会焕 | Traditional Chinese medicine composition for treating miocardial infarction |
| CN104225507A (en) * | 2014-10-13 | 2014-12-24 | 崔银方 | Chinese medicine for treating limb paralysis and pain caused by cerebral hemorrhage |
| CN104887747A (en) * | 2015-07-06 | 2015-09-09 | 苗怡文 | Traditional Chinese medicine composition for treating cerebral thrombosis and preparation method therefor |
| CN104940597A (en) * | 2015-07-27 | 2015-09-30 | 青岛蓝盛洋医药生物科技有限责任公司 | Chinese herbal composition used for treating myocardial infarction, and preparation method of Chinese herbal composition |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105213769A (en) * | 2015-09-29 | 2016-01-06 | 罗奕珺 | A kind of Chinese medicine composition for the treatment of myocardial infarction and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105796685A (en) | 2016-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104491755A (en) | Traditional Chinese medicine composition for treating abdominal distension and preparation method of traditional Chinese medicine composition | |
| CN104971215A (en) | Traditional Chinese medicine composition for treating spleen-deficiency gastrasthenia type chronic gastritis and preparation method thereof | |
| CN104258350A (en) | Traditional Chinese medicine preparation for treating sick sinus syndrome and preparation method of traditional Chinese medicine preparation | |
| CN104940597A (en) | Chinese herbal composition used for treating myocardial infarction, and preparation method of Chinese herbal composition | |
| CN105232677A (en) | Traditional Chinese medicine composition for treating myocardial infarction and preparation method of traditional Chinese medicine composition | |
| CN113209194B (en) | Composition for treating chronic gastritis and preparation method and application thereof | |
| CN108888735B (en) | Traditional Chinese medicine composition for treating chronic constipation | |
| CN103705733B (en) | One treats ARR Chinese medicinal capsule and preparation method thereof | |
| CN104984027A (en) | Chinese materia medica preparation for treating myelodysplastic syndrome and preparation method thereof | |
| CN104873911A (en) | Traditional Chinese medicine for oral administration for adjunctively treating sepsis | |
| CN103330760A (en) | Medicament used for treating allergic purpura | |
| CN105213769A (en) | A kind of Chinese medicine composition for the treatment of myocardial infarction and preparation method thereof | |
| CN105770760A (en) | Preparation for treating gastric ulcer and preparation method thereof | |
| CN105456447A (en) | Folium artemisiae argyi-containing traditional Chinese medicine composition with function of promoting blood circulation to remove stasis and preparation method thereof | |
| CN105687656A (en) | Pharmaceutical composition for treating myelitis and preparation method thereof | |
| CN105288036A (en) | Pharmaceutical composition for treating myocardial infarction and preparing method thereof | |
| CN105311425A (en) | Application of pharmaceutical composition containing folium artemisiae argyi in preparing medicine for treating myocardial infarction | |
| CN104524535A (en) | Traditional Chinese medicine composition for treating chronic pulmonary heart disease and preparation method of traditional Chinese medicine composition | |
| CN104984060A (en) | Traditional Chinese medicament for treating coronary heart disease | |
| CN104784401A (en) | Traditional Chinese medicine preparation for treating stomach cancer | |
| CN104784649A (en) | Traditional Chinese medicine decoction for treating scapulohumeral periarthritis | |
| CN103623271B (en) | A kind of preparation method of eight-ingredient stomach-regulating oral formulations | |
| CN104474449A (en) | Traditional Chinese medicine composition for treating peptic ulcers and preparation method of composition | |
| CN103845671A (en) | Powder for treating heart failure by warming yang and tonifying qi and preparation method thereof | |
| CN105194477A (en) | Preparation method of powder being used for treating coronary heart diseases and having function of promoting blood circulation to remove meridian obstruction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160113 |
|
| WW01 | Invention patent application withdrawn after publication |